凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
莱茵生物(002166)公告正文

莱茵生物:2015年第一季度报告全文

公告日期 2015-04-24
股票简称:莱茵生物 股票代码:002166
                桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文




桂林莱茵生物科技股份有限公司

     2015 年第一季度报告




        2015 年 04 月




                                                                  1
                                    桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文




                         第一节 重要提示


    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真

实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和

连带的法律责任。

    所有董事均已出席了审议本次季报的董事会会议。

    公司负责人秦本军、主管会计工作负责人周庆伟及会计机构负责人(会计主

管人员)张为鹏声明:保证季度报告中财务报表的真实、准确、完整。




                                                                                      2
                                                            桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文




                            第二节 主要财务数据及股东变化

一、主要会计数据和财务指标

公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据
□ 是 √ 否

                                              本报告期               上年同期             本报告期比上年同期增减

营业收入(元)                                    83,343,733.60         67,033,533.56                       24.33%

归属于上市公司股东的净利润(元)                   3,423,633.18           1,077,765.89                     217.66%

归属于上市公司股东的扣除非经常性损
                                                   3,599,044.39            857,884.19                      319.53%
益的净利润(元)

经营活动产生的现金流量净额(元)                  94,251,066.06         69,223,442.35                       36.15%

基本每股收益(元/股)                                      0.03                    0.01                    200.00%

稀释每股收益(元/股)                                      0.03                    0.01                    200.00%

加权平均净资产收益率                                      1.42%                 0.55%                        0.87%

                                             本报告期末              上年度末             本报告期末比上年度末增减

总资产(元)                                   1,500,729,083.51       1,500,502,076.51                       0.02%

归属于上市公司股东的净资产(元)                 242,836,788.42        238,947,082.71                        1.63%



非经常性损益项目和金额
√ 适用 □ 不适用
                                                                                                           单位:元

                         项目                               年初至报告期期末金额                   说明

非流动资产处置损益(包括已计提资产减值准备的冲销部分)                   -49,895.01

计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                         363,400.00
一标准定额或定量享受的政府补助除外)

计入当期损益的对非金融企业收取的资金占用费                               217,500.01

除上述各项之外的其他营业外收入和支出                                    -860,916.21

     少数股东权益影响额(税后)                                         -154,500.00

合计                                                                    -175,411.21                 --

对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公
开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应
说明原因
□ 适用 √ 不适用
公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益
项目界定为经常性损益的项目的情形。

                                                                                                                     3
                                                      桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文


二、报告期末股东总数及前十名股东持股情况表

1、报告期末普通股股东总数及前十名普通股股东持股情况表

                                                                                                          单位:股

报告期末普通股股东总数                                                                                        32,948

                                      前 10 名普通股股东持股情况

                                                             持有有限售条件           质押或冻结情况
   股东名称         股东性质   持股比例       持股数量
                                                               的股份数量        股份状态              数量

秦本军           境内自然人         19.77%      25,613,504        19,210,128 质押                      25,600,000

姚新德           境内自然人          8.71%      11,286,403         8,464,802 质押                       11,285,282

蒋安明           境内自然人          2.39%       3,101,576                  0 质押                       3,100,000

中信证券股份有
                 其他                0.82%       1,060,500                  0
限公司

五矿国际信托有
限公司一五矿信
托一西南鸿晟证 其他                  0.51%        656,512                   0
券投资集合资金
信托计划

杨英伟           境内自然人          0.48%        622,217                   0

邱楚强           境内自然人          0.37%        477,206                   0

五矿国际信托有
限公司一五矿信
托一信诚 1 号证 其他                 0.32%        419,122                   0
券投资集合资金
信托计划

徐庆元           境内自然人          0.31%        400,000                   0

李建敏           境内自然人          0.27%        350,000                   0

                                 前 10 名无限售条件普通股股东持股情况

                                                                                            股份种类
           股东名称                持有无限售条件普通股股份数量
                                                                                 股份种类              数量

秦本军                                                             6,403,376 人民币普通股                6,403,376

蒋安明                                                             3,101,576 人民币普通股                3,101,576

姚新德                                                             2,821,601 人民币普通股                2,821,601

中信证券股份有限公司                                               1,060,500 人民币普通股                1,060,500

五矿国际信托有限公司—五矿信
托—西南鸿晟证券投资集合资金                                        656,512 人民币普通股                  656,512
信托计划


                                                                                                                       4
                                                          桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文


杨英伟                                                                622,217 人民币普通股            622,217

邱楚强                                                                477,206 人民币普通股            477,206

五矿国际信托有限公司一五矿信
托一信诚 1 号证券投资集合资金                                         419,122 人民币普通股            419,122
信托计划

徐庆元                                                                400,000 人民币普通股            400,000

李建敏                                                                350,000 人民币普通股            350,000

上述股东关联关系或一致行动的 公司股东秦本军先生与蒋安明先生为兄弟关系,属于一致行动人,除上述关联关系以外,
说明                            公司前 3 大股东之间不存在关联关系或一致行动,其他股东之间关系不详。

公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易
□ 是 √ 否
公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内未进行约定购回交易。


2、报告期末优先股股东总数及前十名优先股股东持股情况表

□ 适用 √ 不适用




                                                                                                                5
                                                        桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文




                                         第三节 重要事项

一、报告期主要会计报表项目、财务指标发生变动的情况及原因

√ 适用 □ 不适用
1.资产负债表项目变动情况
           项目             期末余额         期初余额         增减比例                   变动原因
货币资金                    26,782,883.33     70,246,510.73      -61.87% 主要是归还银行贷款及偿还暂借款所致
预付账款                    17,288,127.52      4,800,560.19     260.13% 主要系预付新工厂设备款所致
其他流动资产                  4,360,224.18     7,058,824.99      -38.23% 主要系增值税进项留底减少所致
在建工程                      8,031,094.72     5,329,775.00      50.68% 主要系新工厂建设支出增加所致
短期借款                   254,500,000.00    142,778,719.52      78.25% 系银行短期贷款增加所致
预收款项                   393,188,364.42    207,655,816.46      89.35% 主要系报告期BT项目收到1.82亿回购资金
                                                                           所致
                                                                           主要系发放上年度计提的绩效工资及奖金
应付职工薪酬                  1,029,135.77     4,561,446.34      -77.44%
                                                                           所致
其他应付款                  16,212,162.97    129,604,402.39      -87.49% 主要系偿还1.1亿暂借款所致
一年内到期的非流动负债     111,801,460.00    266,801,460.00      -58.10% 系偿还已到期银行贷款所致
长期借款                    65,000,000.00     20,000,000.00     225.00% 系银行长期贷款增加所致
2.利润表项目变动情况
           项目            本期金额          上期金额         增减比例                   变动原因
营业收入                    83,343,733.60     67,033,533.56      24.33% 主要系植物提取物销售额大幅增加所致
营业成本                    67,867,537.06     50,995,414.93      33.09% 系植物提取物销售收入增加成本相应增加
财务费用                      2,197,914.72     5,992,390.50      -63.32% 主要系BT项目资本化利息支出增加所致
投资收益                                        387,586.05      -100.00% 系报告期内尚未收到参股银行上年度投资
                                                                           分红所致
营业外收入                     543,160.75         35,300.00    1438.70% 主要系收到的政府补助增加所致
                                                                           主要系赞助桂林市历史文物建设工程款所
营业外支出                    1,090,571.97        35,151.63    3002.48%
                                                                           致
所得税费用                     118,898.65                       100.00% 系BT项目1季度盈利计提的所得税
其他综合收益                   466,072.53       127,199.12      266.41% 系汇率变动产生的外币报表折算差额
3.现金流量表项目变动情况
           项目            期末余额          期初余额         增减比例                   变动原因
                                                                           主要是本年销售回款及时、收到BT项目
经营活动现金流量净额        94,251,066.06     69,223,442.35      36.15%
                                                                           1.82亿元回购资金所致
                                                                           主要是支付新工厂土地款、土建工程款及
投资活动现金流量净额        -20,089,443.23      372,808.05     -5488.68%
                                                                           设备款所致
筹资活动现金流量净额       -117,537,543.75   -94,401,028.50      -24.51% 主要是归还银行贷款及偿还暂借款所致




                                                                                                              6
                                                            桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文


二、重要事项进展情况及其影响和解决方案的分析说明

√ 适用 □ 不适用

     1.嘉吉公司订单
     2011年11月4日,公司披露了《关于签订日常经营重大合同的公告》。公司及全资子公司LAYN USA
与美国嘉吉股份有限公司营养健康事业部签订了一份关于甜菊糖最终产品的长期独家《外包加工及供应协
议》。根据协议的相关约定,该协议已经续约至2017年11月1日止。2015年1季度,公司与美国嘉吉公司执
行订单总计约454万美元。
     2.BT项目合同
     2011年8月30日,公司披露了《关于全资子公司桂林莱茵投资有限公司签订BT项目合同的公告》。莱
茵投资与湖南省建筑工程集团总公司、湖南省建工园林工程有限公司组成的联合体与桂林市临桂新区管理
委员会、桂林市临桂新区城市建设投资有限公司、桂林市大禹水利基础设施建设投资有限公司签订了《桂
林市临桂新区防洪排涝及湖塘水系工程投资、建设与移交合同书》,BT项目总投资估算约为人民币16.2亿
元,建安总投资不低于人民币13.2亿元,其余3亿元为工程建设其他费用(综合费用)。
     截至2015年3月31日,BT项目累计完成工程产值约7.1亿元。2015年2月16日,莱茵投资收到BT项目工
程回购款1.82亿元。截至本报告披露日,已累计收到回购款4.32亿元。2015年1季度,莱茵投资实现营业收
入3,389,161.07元,净利润673,759.05元。
     3.非公开发行股票事项
     2015年4月2日,公司收到中国证监会《关于核准桂林莱茵生物科技股份有限公司非公开发行股票的批
复》(证监许可[2015]456号),批复核准公司非公开发行不超过35,508,915股新股。
     目前,公司董事会正积极推进本次非公开发行股票的相关事宜。
      重要事项概述              披露日期                                 临时报告披露网站查询索引

                                                   巨潮资讯网(www.cninfo.com.cn),《BT 项目合同实施进展公告》(公
BT 项目                 2015 年 04 月 08 日
                                                   告编号 2015-016)。

                                                   巨潮资讯网(www.cninfo.com.cn),《关于非公开发行股票获得中国
非公开发行股票          2015 年 04 月 03 日
                                                   证券监督管理委员会核准批复的公告》(公告编号 2015-015)。


三、公司或持股 5%以上股东在报告期内发生或以前期间发生但持续到报告期内的承诺事项

√ 适用 □ 不适用

       承诺事由             承诺方                    承诺内容                  承诺时间 承诺期限       履行情况

股改承诺

收购报告书或权益变动
报告书中所作承诺

资产重组时所作承诺

                                           本公司上市时,当时持有本公司 5%
                                           以上股份的股东秦本军、姚新德、
                                           杨晓涛及蒋安明向本公司出具了                             截至本报告披露
首次公开发行或再融资   秦本军、姚新德、                                        2007 年 09
                                           《避免同业竞争承诺函》,承诺:"                  长期履行 日,该承诺正在
时所作承诺             杨晓涛及蒋安明                                          月 13 日
                                           本人将不在中国境内外直接或间接                           履行。
                                           从事或参与任何在商业上对股份公
                                           司构成竞争的业务或活动,或拥有


                                                                                                                      7
                                                           桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文


                                        与股份公司存在竞争关系的任何经
                                        济实体、机构、经济组织的权益,
                                        或以其他任何形式取得该经济实
                                        体、机构、经济组织的控制权,或
                                        在该经济实体、机构、经济组织中
                                        担任高级管理人员或核心技术人
                                        员。"

其他对公司中小股东所
作承诺

承诺是否及时履行       是




四、对 2015 年 1-6 月经营业绩的预计

2015 年 1-6 月预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形

2015 年 1-6 月归属于上市公司股东的净利润变动幅度                               0   至                     30%

2015 年 1-6 月归属于上市公司股东的净利润变动区间(万元)                 1475.19   至                 1,917.75

2014 年 1-6 月归属于上市公司股东的净利润(万元)                                                      1,475.19

                                                       随着公司前期战略调整规划的深入落实,公司预计植物提取
                                                       物销售较上年相比将取得一定的增长,尤其是以罗汉果提取
业绩变动的原因说明
                                                       物为代表的天然甜味剂产品将为公司业绩增长做出较大贡
                                                       献。


五、证券投资情况

□ 适用 √ 不适用
公司报告期不存在证券投资。


六、持有其他上市公司股权情况的说明

□ 适用 √ 不适用
公司报告期未持有其他上市公司股权。




                                                                                                                 8
                                                        桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文




                                         第四节 财务报表

一、财务报表

1、合并资产负债表

编制单位:桂林莱茵生物科技股份有限公司
                                                                                                     单位:元

                 项目                        期末余额                               期初余额

流动资产:

    货币资金                                             26,782,883.33                          70,246,510.73

    结算备付金

    拆出资金

    以公允价值计量且其变动计入当
期损益的金融资产

    衍生金融资产

    应收票据

    应收账款                                             58,772,022.31                          55,009,856.51

    预付款项                                             17,288,127.52                           4,800,560.19

    应收保费

    应收分保账款

    应收分保合同准备金

    应收利息                                              9,352,484.82                           9,134,984.81

    应收股利

    其他应收款                                           29,266,764.85                          25,058,998.46

    买入返售金融资产

    存货                                                850,155,947.88                         825,461,445.35

    划分为持有待售的资产

    一年内到期的非流动资产

    其他流动资产                                          4,360,224.18                           7,058,824.99

流动资产合计                                            995,978,454.89                         996,771,181.04

非流动资产:

    发放贷款及垫款

    可供出售金融资产                                     33,307,092.50                          33,307,092.50



                                                                                                                9
                                   桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文


    持有至到期投资

    长期应收款                       15,960,000.00                        14,500,000.00

    长期股权投资

    投资性房地产                    262,208,502.49                       263,301,024.67

    固定资产                        133,800,453.02                       136,329,276.36

    在建工程                           8,031,094.72                        5,329,775.00

    工程物资

    固定资产清理

    生产性生物资产

    油气资产

    无形资产                         45,052,873.43                        44,462,733.17

    开发支出

    商誉

    长期待摊费用                        662,287.76                          772,669.07

    递延所得税资产                     5,728,324.70                        5,728,324.70

    其他非流动资产

非流动资产合计                      504,750,628.62                       503,730,895.47

资产总计                           1,500,729,083.51                    1,500,502,076.51

流动负债:

    短期借款                        254,500,000.00                       142,778,719.52

    向中央银行借款

    吸收存款及同业存放

    拆入资金

    以公允价值计量且其变动计入当
期损益的金融负债

    衍生金融负债

    应付票据

    应付账款                        188,214,942.14                       260,204,496.09

    预收款项                        393,188,364.42                       207,655,816.46

    卖出回购金融资产款

    应付手续费及佣金

    应付职工薪酬                       1,029,135.77                        4,561,446.34

    应交税费                           5,492,776.79                        6,014,608.67

    应付利息                            595,166.67                           799,167.11




                                                                                     10
                             桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文


    应付股利

    其他应付款                 16,212,162.97                       129,604,402.39

    应付分保账款

    保险合同准备金

    代理买卖证券款

    代理承销证券款

    划分为持有待售的负债

    一年内到期的非流动负债    111,801,460.00                       266,801,460.00

    其他流动负债                 8,197,735.32                        9,472,181.12

流动负债合计                  979,231,744.08                     1,027,892,297.70

非流动负债:

    长期借款                   65,000,000.00                        20,000,000.00

    应付债券

      其中:优先股

               永续债

    长期应付款

    长期应付职工薪酬

    专项应付款                179,909,426.92                       179,909,426.92

    预计负债                     5,800,074.03                        5,800,074.03

    递延收益                   26,430,102.00                        26,430,102.00

    递延所得税负债               1,370,247.72                        1,370,247.72

    其他非流动负债

非流动负债合计                278,509,850.67                       233,509,850.67

负债合计                     1,257,741,594.75                    1,261,402,148.37

所有者权益:

    股本                      129,533,760.00                       129,533,760.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                   83,217,530.86                        83,217,530.86

    减:库存股

    其他综合收益                   -79,543.98                         -545,616.51

    专项储备

    盈余公积                     8,834,943.24                        8,834,943.24



                                                                                11
                                                       桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文


    一般风险准备

    未分配利润                                           21,330,098.30                          17,906,465.12

归属于母公司所有者权益合计                              242,836,788.42                         238,947,082.71

    少数股东权益                                            150,700.34                             152,845.43

所有者权益合计                                          242,987,488.76                         239,099,928.14

负债和所有者权益总计                                   1,500,729,083.51                       1,500,502,076.51


法定代表人:秦本军                 主管会计工作负责人:周庆伟                      会计机构负责人:张为鹏


2、母公司资产负债表

                                                                                                      单位:元

                 项目                       期末余额                               期初余额

流动资产:

    货币资金                                             22,377,661.17                          67,274,233.48

    以公允价值计量且其变动计入当
期损益的金融资产

    衍生金融资产

    应收票据

    应收账款                                             70,133,478.96                          82,967,085.15

    预付款项                                             11,753,163.55                            1,837,424.58

    应收利息

    应收股利

    其他应收款                                           28,567,017.25                          24,950,824.85

    存货                                                186,887,436.85                         191,738,113.81

    划分为持有待售的资产

    一年内到期的非流动资产

    其他流动资产                                           4,356,397.33                           7,055,405.14

流动资产合计                                            324,075,155.11                         375,823,087.01

非流动资产:

    可供出售金融资产                                     33,307,092.50                          33,307,092.50

    持有至到期投资

    长期应收款

    长期股权投资                                        118,154,924.59                         118,154,924.59

    投资性房地产                                        262,208,502.49                         263,301,024.67

    固定资产                                            130,007,927.49                         132,382,592.25


                                                                                                            12
                                   桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文


    在建工程                         7,659,796.72                          4,958,477.00

    工程物资

    固定资产清理

    生产性生物资产

    油气资产

    无形资产                        44,151,669.02                         43,537,246.67

    开发支出

    商誉

    长期待摊费用

    递延所得税资产                   5,723,840.22                          5,723,840.22

    其他非流动资产

非流动资产合计                     601,213,753.03                        601,365,197.90

资产总计                           925,288,908.14                        977,188,284.91

流动负债:

    短期借款                       104,500,000.00                        122,778,719.52

    以公允价值计量且其变动计入当
期损益的金融负债

    衍生金融负债

    应付票据

    应付账款                        26,293,352.12                         37,652,290.98

    预收款项                         3,953,811.82                           423,003.86

    应付职工薪酬                       660,846.00                          3,384,339.00

    应交税费                            48,100.59                           685,272.37

    应付利息                                                                338,083.78

    应付股利

    其他应付款                     301,145,193.23                        314,418,829.15

    划分为持有待售的负债

    一年内到期的非流动负债          11,801,460.00                         66,801,460.00

    其他流动负债

流动负债合计                       448,402,763.76                        546,481,998.66

非流动负债:

    长期借款                        65,000,000.00                         20,000,000.00

    应付债券

      其中:优先股




                                                                                     13
                                       桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文


               永续债

    长期应付款

    长期应付职工薪酬

    专项应付款                         179,909,426.92                          179,909,426.92

    预计负债                                5,800,074.03                         5,800,074.03

    递延收益                               26,430,102.00                        26,430,102.00

    递延所得税负债

    其他非流动负债

非流动负债合计                         277,139,602.95                          232,139,602.95

负债合计                               725,542,366.71                          778,621,601.61

所有者权益:

    股本                               129,533,760.00                          129,533,760.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                               83,217,530.86                        83,217,530.86

    减:库存股

    其他综合收益

    专项储备

    盈余公积                                8,834,943.24                         8,834,943.24

    未分配利润                             -21,839,692.67                      -23,019,550.80

所有者权益合计                         199,746,541.43                          198,566,683.30

负债和所有者权益总计                   925,288,908.14                          977,188,284.91


3、合并利润表

                                                                                     单位:元

                 项目         本期发生额                          上期发生额

一、营业总收入                              83,343,733.60                       67,033,533.56

    其中:营业收入                          83,343,733.60                       67,033,533.56

           利息收入

           已赚保费

           手续费及佣金收入

二、营业总成本                              79,255,935.64                       66,347,597.28

    其中:营业成本                          67,867,537.06                       50,995,414.93



                                                                                           14
                                         桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文


             利息支出

             手续费及佣金支出

             退保金

             赔付支出净额

             提取保险合同准备金净额

             保单红利支出

             分保费用

             营业税金及附加                -1,274,445.80                          157,799.80

             销售费用                       2,568,788.10                         2,105,543.99

             管理费用                       7,896,141.56                         7,096,448.06

             财务费用                       2,197,914.72                         5,992,390.50

             资产减值损失

    加:公允价值变动收益(损失以
“-”号填列)

         投资收益(损失以“-”号填
                                                                                  387,586.05
列)

         其中:对联营企业和合营企业
的投资收益

         汇兑收益(损失以“-”号填列)

三、营业利润(亏损以“-”号填列)          4,087,797.96                         1,073,522.33

    加:营业外收入                           543,160.75                            35,300.00

         其中:非流动资产处置利得

    减:营业外支出                          1,090,571.97                           35,151.63

         其中:非流动资产处置损失             49,895.01                            34,151.63

四、利润总额(亏损总额以“-”号填列)      3,540,386.74                         1,073,670.70

    减:所得税费用                           118,898.65

五、净利润(净亏损以“-”号填列)          3,421,488.09                         1,073,670.70

    归属于母公司所有者的净利润              3,423,633.18                         1,077,765.89

    少数股东损益                               -2,145.09                            -4,095.19

六、其他综合收益的税后净额                   466,072.53                           127,199.12

  归属母公司所有者的其他综合收益
                                             466,072.53                           127,199.12
的税后净额

    (一)以后不能重分类进损益的其
他综合收益

             1.重新计量设定受益计划净
负债或净资产的变动


                                                                                           15
                                                          桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文


             2.权益法下在被投资单位不
能重分类进损益的其他综合收益中享
有的份额

    (二)以后将重分类进损益的其他
                                                                466,072.53                          127,199.12
综合收益

             1.权益法下在被投资单位以
后将重分类进损益的其他综合收益中
享有的份额

             2.可供出售金融资产公允价
值变动损益

             3.持有至到期投资重分类为
可供出售金融资产损益

             4.现金流量套期损益的有效
部分

             5.外币财务报表折算差额                             466,072.53                          127,199.12

             6.其他

  归属于少数股东的其他综合收益的
税后净额

七、综合收益总额                                              3,887,560.62                         1,200,869.82

    归属于母公司所有者的综合收益
                                                              3,889,705.71                         1,204,965.01
总额

    归属于少数股东的综合收益总额                                 -2,145.09                            -4,095.19

八、每股收益:

    (一)基本每股收益                                                0.03                                 0.01

    (二)稀释每股收益                                                0.03                                 0.01

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:元,上期被合并方实现的净利润为:元。


法定代表人:秦本军                      主管会计工作负责人:周庆伟                    会计机构负责人:张为鹏


4、母公司利润表

                                                                                                       单位:元

                 项目                           本期发生额                           上期发生额

一、营业收入                                                 52,525,759.78                        59,838,933.73

    减:营业成本                                             41,642,170.31                        45,298,340.81

           营业税金及附加                                                                                27.56

           销售费用                                           1,508,978.59                         1,365,637.81

           管理费用                                           6,645,207.11                         5,872,017.03


                                                                                                             16
                                      桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文


         财务费用                       2,032,134.42                          1,962,222.30

         资产减值损失

    加:公允价值变动收益(损失以
“-”号填列)

         投资收益(损失以“-”号填
                                                                               387,586.05
列)

         其中:对联营企业和合营企
业的投资收益

二、营业利润(亏损以“-”号填列)        697,269.35                          5,728,274.27

    加:营业外收入                        543,160.75                            33,800.00

         其中:非流动资产处置利得

    减:营业外支出                         60,571.97                            34,151.63

         其中:非流动资产处置损失          49,895.01                            34,151.63

三、利润总额(亏损总额以“-”号填
                                        1,179,858.13                          5,727,922.64
列)

    减:所得税费用

四、净利润(净亏损以“-”号填列)      1,179,858.13                          5,727,922.64

五、其他综合收益的税后净额

    (一)以后不能重分类进损益的
其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

    (二)以后将重分类进损益的其
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额



                                                                                        17
                                                 桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文


           6.其他

六、综合收益总额                                    1,179,858.13                           5,727,922.64

七、每股收益:

     (一)基本每股收益                                     0.01                                   0.04

     (二)稀释每股收益                                     0.01                                   0.04


5、合并现金流量表

                                                                                               单位:元

               项目                 本期发生额                           上期金额发生额

一、经营活动产生的现金流量:

     销售商品、提供劳务收到的现金                264,426,296.39                        191,110,793.37

     客户存款和同业存放款项净增
加额

     向中央银行借款净增加额

     向其他金融机构拆入资金净增
加额

     收到原保险合同保费取得的现


     收到再保险业务现金净额

     保户储金及投资款净增加额

     处置以公允价值计量且其变动
计入当期损益的金融资产净增加额

     收取利息、手续费及佣金的现金

     拆入资金净增加额

     回购业务资金净增加额

     收到的税费返还                                6,391,817.24                            2,179,748.87

     收到其他与经营活动有关的现
                                                    828,817.97                              273,036.42


经营活动现金流入小计                             271,646,931.60                        193,563,578.66

     购买商品、接受劳务支付的现金                152,189,011.78                           99,283,117.67

     客户贷款及垫款净增加额

     存放中央银行和同业款项净增
加额

     支付原保险合同赔付款项的现


     支付利息、手续费及佣金的现金


                                                                                                     18
                                    桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文


     支付保单红利的现金

     支付给职工以及为职工支付的
                                     12,284,648.05                         11,916,982.46
现金

     支付的各项税费                    712,695.57                           2,259,720.55

     支付其他与经营活动有关的现
                                     12,209,510.14                         10,880,315.63


经营活动现金流出小计                177,395,865.54                        124,340,136.31

经营活动产生的现金流量净额           94,251,066.06                         69,223,442.35

二、投资活动产生的现金流量:

     收回投资收到的现金

     取得投资收益收到的现金                                                  387,586.05

     处置固定资产、无形资产和其他
                                                                               35,500.00
长期资产收回的现金净额

     处置子公司及其他营业单位收
到的现金净额

     收到其他与投资活动有关的现
                                      3,216,000.00                           600,000.00


投资活动现金流入小计                  3,216,000.00                          1,023,086.05

     购建固定资产、无形资产和其他
                                     23,305,443.23                           650,278.00
长期资产支付的现金

     投资支付的现金

     质押贷款净增加额

     取得子公司及其他营业单位支
付的现金净额

     支付其他与投资活动有关的现


投资活动现金流出小计                 23,305,443.23                           650,278.00

投资活动产生的现金流量净额          -20,089,443.23                           372,808.05

三、筹资活动产生的现金流量:

     吸收投资收到的现金

     其中:子公司吸收少数股东投资
收到的现金

     取得借款收到的现金             195,000,000.00                         16,636,890.00

     发行债券收到的现金

     收到其他与筹资活动有关的现
                                                                           35,604,800.00





                                                                                      19
                                                 桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文


筹资活动现金流入小计                             195,000,000.00                          52,241,690.00

     偿还债务支付的现金                          193,467,952.61                         102,867,765.17

     分配股利、利润或偿付利息支付
                                                   9,069,591.14                           9,487,996.66
的现金

     其中:子公司支付给少数股东的
股利、利润

     支付其他与筹资活动有关的现
                                                 110,000,000.00                          34,286,956.67


筹资活动现金流出小计                             312,537,543.75                         146,642,718.50

筹资活动产生的现金流量净额                   -117,537,543.75                            -94,401,028.50

四、汇率变动对现金及现金等价物的
                                                     -87,706.48                              23,738.45
影响

五、现金及现金等价物净增加额                     -43,463,627.40                         -24,781,039.65

     加:期初现金及现金等价物余额                 70,246,510.73                          38,680,937.10

六、期末现金及现金等价物余额                      26,782,883.33                          13,899,897.45


6、母公司现金流量表

                                                                                              单位:元

              项目                  本期发生额                             上期发生额

一、经营活动产生的现金流量:

     销售商品、提供劳务收到的现金                 72,856,627.17                          68,570,076.74

     收到的税费返还                                6,391,817.24                           2,179,748.87

     收到其他与经营活动有关的现
                                                    412,761.52                               58,924.87


经营活动现金流入小计                              79,661,205.93                          70,808,750.48

     购买商品、接受劳务支付的现金                 46,466,970.56                          40,095,045.57

     支付给职工以及为职工支付的
                                                   9,671,347.42                           9,482,678.20
现金

     支付的各项税费                                 684,090.80                            1,249,445.21

     支付其他与经营活动有关的现
                                                   5,874,732.90                           6,174,177.79


经营活动现金流出小计                              62,697,141.68                          57,001,346.77

经营活动产生的现金流量净额                        16,964,064.25                          13,807,403.71

二、投资活动产生的现金流量:

     收回投资收到的现金

     取得投资收益收到的现金                                                                387,586.05


                                                                                                    20
                                    桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文


     处置固定资产、无形资产和其他
                                                                               35,500.00
长期资产收回的现金净额

     处置子公司及其他营业单位收
到的现金净额

     收到其他与投资活动有关的现
                                     3,216,000.00                            600,000.00


投资活动现金流入小计                 3,216,000.00                           1,023,086.05

     购建固定资产、无形资产和其他
                                    22,792,695.23                            650,278.00
长期资产支付的现金

     投资支付的现金

     取得子公司及其他营业单位支
付的现金净额

     支付其他与投资活动有关的现


投资活动现金流出小计                22,792,695.23                            650,278.00

投资活动产生的现金流量净额          -19,576,695.23                           372,808.05

三、筹资活动产生的现金流量:

     吸收投资收到的现金

     取得借款收到的现金             45,000,000.00                          16,636,890.00

     发行债券收到的现金

     收到其他与筹资活动有关的现
                                    10,500,000.00                          72,000,000.00


筹资活动现金流入小计                55,500,000.00                          88,636,890.00

     偿还债务支付的现金             73,467,952.61                         102,867,765.17

     分配股利、利润或偿付利息支付
                                     2,911,674.47                           2,315,467.30
的现金

     支付其他与筹资活动有关的现
                                    21,310,000.00                          25,000,000.00


筹资活动现金流出小计                97,689,627.08                         130,183,232.47

筹资活动产生的现金流量净额          -42,189,627.08                        -41,546,342.47

四、汇率变动对现金及现金等价物的
                                        -94,314.25                             13,402.83
影响

五、现金及现金等价物净增加额        -44,896,572.31                        -27,352,727.88

     加:期初现金及现金等价物余额   67,274,233.48                          36,159,744.42

六、期末现金及现金等价物余额        22,377,661.17                           8,807,016.54




                                                                                      21
                             桂林莱茵生物科技股份有限公司 2015 年第一季度报告全文


二、审计报告

第一季度报告是否经过审计
□ 是 √ 否
公司第一季度报告未经审计。




                                          桂林莱茵生物科技股份有限公司


                                          法定代表人:

                                                                  秦本军

                                                           2015 年 4 月 22 日




                                                                              22
数据加载中...
prevnext
手机查看股票